

ICER publishes draft scoping report on COVID-19 treatments

The Institute for Clinical and Economic Review (ICER) has announced plans to review the comparative clinical and cost effectiveness and five treatments used for COVID-19: casirivimab/imdevimab [REGEN-CON; Regeneron]; sotrovimab [GlaxoSmithKline and Vir Biotechnology]; molnupiravir [Merck]; PF-07321332/ritonavir [Pfizer]; and, fluvoxamine (Investigator initiated).

The draft scoping document is the result of 5 weeks' engagement with key stakeholders, including the drug manufacturers, clinical specialists, and payers, and outlines how ICER plans to conduct this assessment.

ICER hopes to include submissions from stakeholders on examples of low-value care practices within this clinical area, which will inform a report section focused on strategies to reduce waste and preserve resources for high-value, more costly treatments.

The draft document will be open to public comment until September 15, with revisions published at the end of September 2021.